N Wu1, F Fu2, L Chen1, Y Lin1, P Yang1, C Wang3. 1. Department of General Surgery, Affiliated Union Hospital of Fujian Medical University, No. 29, Xin Quan Road, Gulou District, Fuzhou, 350001, Fujian, China. 2. Department of General Surgery, Affiliated Union Hospital of Fujian Medical University, No. 29, Xin Quan Road, Gulou District, Fuzhou, 350001, Fujian, China. 412555736@qq.com. 3. Department of General Surgery, Affiliated Union Hospital of Fujian Medical University, No. 29, Xin Quan Road, Gulou District, Fuzhou, 350001, Fujian, China. chuanwang1968@outlook.com.
Abstract
BACKGROUND: The prognostic and clinical significance of single hormone receptor expression in breast cancer has not been clearly established. The goal of this study was to conduct a meta-analysis to compare the clinical outcomes of patients with ER+PR- tumours and ER-PR+ tumours to those of patients with ER+PR+ tumours. METHODS: A systematic review of the literature was conducted to identify studies that compared the clinical outcome of patients with ER+PR- tumours or ER-PR+ tumours with those of patients with ER+PR+ tumours. A total of 18 studies met the inclusion criteria and included 217,485 women. Standard methods for meta-analysis were used, including fixed-effect models. RESULTS: Patients with ER+PR- tumours or ER-PR+ tumours had significantly worse DFS (HR 1.60, 95% CI 1.44-1.77 and HR 2.27, 95% CI 1.67-3.09), BCSS (HR 1.43, 95% CI 1.33-1.53 and HR 1.82, 95% CI 1.68-1.98) and OS (HR 1.38, 95% CI 1.28-1.47 and HR 1.48, 95% CI 1.17-1.89) than those of patients with ER+PR+ tumours. In subgroup analyses, patients who had ER+PR- tumours experienced a higher risk of recurrence than patients with ER+PR+ tumours in the HER2- (HR 1.57, 95% CI 1.32-1.87), LN - (HR 2.07, 95% CI 1.44-2.86) and endocrine therapy (HR 1.65, 95% CI 1.45-1.89) subgroup. Patients who had HER2- and ER-PR+ tumours had an increased risk of recurrence compared with patients who had HER2- and ER+PR+ tumours (HR 3.10, 95% CI 1.92-5.10). CONCLUSIONS: Among patients with hormone receptor-positive breast cancer, patients with either ER+PR- tumours or ER-PR+ tumours have a higher risk of recurrence and a shorter survival time than those with ER+PR+ tumours. Patients with both types of breast cancer need additional or better treatments.
BACKGROUND: The prognostic and clinical significance of single hormone receptor expression in breast cancer has not been clearly established. The goal of this study was to conduct a meta-analysis to compare the clinical outcomes of patients with ER+PR- tumours and ER-PR+ tumours to those of patients with ER+PR+ tumours. METHODS: A systematic review of the literature was conducted to identify studies that compared the clinical outcome of patients with ER+PR- tumours or ER-PR+ tumours with those of patients with ER+PR+ tumours. A total of 18 studies met the inclusion criteria and included 217,485 women. Standard methods for meta-analysis were used, including fixed-effect models. RESULTS:Patients with ER+PR- tumours or ER-PR+ tumours had significantly worse DFS (HR 1.60, 95% CI 1.44-1.77 and HR 2.27, 95% CI 1.67-3.09), BCSS (HR 1.43, 95% CI 1.33-1.53 and HR 1.82, 95% CI 1.68-1.98) and OS (HR 1.38, 95% CI 1.28-1.47 and HR 1.48, 95% CI 1.17-1.89) than those of patients with ER+PR+ tumours. In subgroup analyses, patients who had ER+PR- tumours experienced a higher risk of recurrence than patients with ER+PR+ tumours in the HER2- (HR 1.57, 95% CI 1.32-1.87), LN - (HR 2.07, 95% CI 1.44-2.86) and endocrine therapy (HR 1.65, 95% CI 1.45-1.89) subgroup. Patients who had HER2- and ER-PR+ tumours had an increased risk of recurrence compared with patients who had HER2- and ER+PR+ tumours (HR 3.10, 95% CI 1.92-5.10). CONCLUSIONS: Among patients with hormone receptor-positive breast cancer, patients with either ER+PR- tumours or ER-PR+ tumours have a higher risk of recurrence and a shorter survival time than those with ER+PR+ tumours. Patients with both types of breast cancer need additional or better treatments.
Entities:
Keywords:
Breast cancer; Breast cancer-specific survival; Disease-free survival; Estrogen receptor; Hormone receptor positive; Overall survival; Progesterone receptor
Authors: Sian Tovey; Barbara Dunne; Caroline J Witton; Amanda Forsyth; Timothy G Cooke; John M S Bartlett Journal: Clin Cancer Res Date: 2005-07-01 Impact factor: 12.531
Authors: Emad A Rakha; Maysa E El-Sayed; Andrew R Green; E Claire Paish; Desmond G Powe; Julia Gee; Robert I Nicholson; Andrew H S Lee; John F R Robertson; Ian O Ellis Journal: J Clin Oncol Date: 2007-09-17 Impact factor: 44.544
Authors: Rachel Schiff; Suleiman A Massarweh; Jiang Shou; Lavina Bharwani; Syed K Mohsin; C Kent Osborne Journal: Clin Cancer Res Date: 2004-01-01 Impact factor: 12.531
Authors: C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto Journal: Lancet Date: 2011-07-28 Impact factor: 79.321
Authors: Andliena Tahiri; Xavier Tekpli; Somisetty V Satheesh; Rik DeWijn; Torben Lüders; Ida R Bukholm; Antoni Hurtado; Jürgen Geisler; Vessela N Kristensen Journal: Breast Cancer Res Treat Date: 2020-07-24 Impact factor: 4.872
Authors: Ki-Tae Hwang; Young Jin Suh; Chan-Heun Park; Young Joo Lee; Jee Ye Kim; Jin Hyang Jung; Seeyeong Kim; Junwon Min Journal: Oncologist Date: 2021-09-02